Apoptosis and apoptosis-related proteins (Fas, Fas ligand, bcl-2, p53) in macrophages of human ovarian epithelial tumors

Apoptosis and the apoptosis-related proteins (ARP) (Fas, Fas ligand (FasL), bcl-2 and p53) were analyzed in macrophages of different human ovarian epithelial tumors. Few macrophages were found in ovaries of women without oncologic disorders. In ovarian benign cysts, macrophagic density reached 4.9+/-1.2 per 50,000 microm2, most were present in lymphoid-macrophagic infiltrates of the sub-epithelial stroma (3.7+/-0.5% of the area of a slide), and 23.4% were Fas and FasL positive. In borderline tumors, the expanse of lymphoid infiltrates increased to 15.6% of the area of a slide, and the number of macrophages increased 2.4-fold compared to benign cysts. Of the macrophages, 83-88% expressed Fas and FasL, few had bcl-2 and CD25 receptors, and isolated ones were apoptotic. In carcinomas with high lymphoid-macrophagic infiltration, the infiltrate occupied 17.5% of the slide and macrophages amounted to 12.1+/-1.5/50,000 microm2. Many macrophages were in regions of grouping apoptosis of tumor epithelial cells and significantly fewer expressed Fas, FasL and bcl-2. Macrophages destroyed by apoptosis accounted for 4.6%. In carcinomas with low lymphoid-macrophageal infiltration, the area of the last was 5.1% of the slide. There were 8.6+/-0.8 macrophages/50,000 microm2, mainly at the margins of zones of necrosis and of tumor cells' grouping apoptosis. Extensive macrophagic infiltration into tumor parenchyma is one way by which the host immune system destroys tumors. Fas and FasL appear in macrophages of benign cysts, but in borderline tumors and in carcinomas with low infiltration their concentration increases sharply, to 79.8% and 96.6%, respectively. In 4.5% of these cells, apoptosis of macrophages was seen. The findings suggest that macrophages participate in the transfer of ARP to tumor epithelial cells, thereby inducing their apoptosis, but undergoing the simultaneous apoptosis.

Apoptosis; Bcl-2; Fas; Fas ligand; Macrophages; Ovarian tumors

[1] Valkovic T., Lucin K., Krstulja M., Dobi-Babic R., Jonjic N.: "Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer". Path. Res. Pract., 1998, 194, 335.

[2] Jonjic N., Yalkovic T., Lucin K., lternicka Z., Krstulja M., Mustac E., Dobi-Babic R. et al.: "Comparison of microvessel density with tumor associated macrophages in invasive breast carcinoma". Anticancer Res., 1998, 18, 3767.

[3] Mor G., Yue W., Santen R. J., Gutierrez L., Eliza M., Bernstein L., Harada N. et al.: "Macrophages, estrogen and the microenvironment of b reast cancer". J. Steroid. Biochem. Mol. Biol., 1998, 67, 403.

[4] Leber T. M., Balkwill F. R.: "Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF)". Br. J. Cancer, 1998, 78, 724.

[5] Mor G., Gutie订ez L. S., Eliza M., Kahyaogili F.,Arici A.: "Induction of apoptosis mediated by the Fas-Fas ligand system in human placental trophoblast and gestational trophoblastic disease". Am. J. Reprod. lmmunol., 1998, 40, 89.

[6] Gutierrez L., Eliza M., Niven-Fairchild T., Mor G.: "Fas/Fasligand system induced apoptosis in human breast carcinoma: a mechanism for immune evasion". Breast Cancer Res. Treatment, 1999, 54, 245.

[7] Liu D. L., Yang M. Q., Eberhardt J., Persson B.: "Repeated immunotherapy using intratumoral injection with recombinant interleukin-2 and tumor-infiltrating lymphocytes". Cancer Lett., 1996, 103, 131.

[8] Ridolfi R., Flamini E., Ricobon A., DePaola F., Maltoni R., Gardini A., Ridolfi L. et al.: "Adjuvant adaptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients". Cancer lmmunol. lmmunother., 1998, 46, 185

[9] Zhang X. D., Schiller G. D., Gill P. G., Conventry B. J.: "Lymphoid cell infiltration during breast cancer growth: a syngeneic rat mode1". Jmmunol. Cell. Biol., 1998, 76, 550

[10] Ben-Hur H., Gurevich P., Huszar M., Berman V., Tendler Y., Ben-Arie A., Zinder 0. et al.: "Apoptosis and apoptoticrelated proteins (Fas, Fas ligand, bcl-2, p53) in lymphoid elements of human ovarian epithelial tumors". Eur. J. Gynaec. Oneal., 1999a, 21.

[11] Spielman J., Lee R. K., Podack E. R.: "Perforin/Fas-ligand double deficiency is associated with macrophage expansion and severe pancreatitis". J. lmmunol., 1998, 161, 7063.

[12] Elgert K. D., Alleva D. G., Mullins D. W.: "Tumor-induced immune dysfunction: the macrophage connection". J Leukocite Biol., 1998, 64, 275.

[13] Orre M., Rogers P. A. W.: "Macrophages and microvessel density in tumors of the ovary". Gynecol. Oncol., 1999, 73, 47.

[14] Senturk L. M., Seli E., Gutierrez L. M., Mor G., Zeyneloglu H. B., Arici A.: "Monocyte chemoattractant protein-I expression in human corpus luteum". Mo/. Hum. Reprod., 1999, 5, 697.

[15] Harmey J. H., Dimitriadis E., Kay E., Redmond H. P., Bouchier-Hayes D.: "Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta- 1 ". Ann. Surg. Oneal., 1998, 5 ,271.

[16] Negus R. P., Stamp G. W., Hadley J., Balk will F. R.: "Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines". Am. J. Path., 1997, 150, 1723.

[17] Merogi A. J., Marrogi A. J., Ramesh R., Robinson W. R., Fermin C. D.,F reeman S. M.: "Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas". Hum. Path., 1997, 28, 321.

[18] Garcia-Velasces J., Arici A., Naftolin F., Zreick T., Mor G.: "Macrophage-derived growth factor、regulate Fas Ligand expression in endometrial stromal cells. A role in endometriosis". Mol. Hum. Reprod., 1999, 5, 642.

[19] Ben-Hur H., Gurevich P., Huszar M., Berman V., Ben-Ane A., Tendler Y., Zinder 0. et al.: "Expression of apoptosis and apoptosis-related proteins in epithelial cells of human ovarian tumors: immunohistochemical and morphometric studies". Eur. J. Gynaec. Oneal., 1999b, 20, 249.